Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: Relevance to clinical trials
- 29 February 1988
- journal article
- Published by Elsevier BV in European Journal of Cancer and Clinical Oncology
- Vol. 24 (2), 211-218
- https://doi.org/10.1016/0277-5379(88)90255-6
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of AmsacrineEuropean Journal of Cancer and Clinical Oncology, 1987
- Estimation and prediction of cell cycle specific effects of anticancer drugsMathematical Biosciences, 1986
- Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinomaEuropean Journal of Cancer and Clinical Oncology, 1985
- The use of human cancer cell lines as a primary screening system for antineoplastic compoundsEuropean Journal of Cancer and Clinical Oncology, 1984
- Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in miceEuropean Journal of Cancer and Clinical Oncology, 1983
- Dose: A critical factor in cancer chemotherapyThe American Journal of Medicine, 1980
- A rapid single step staining technique for DNA analysis by flow microfluorimetry.Journal of Histochemistry & Cytochemistry, 1980
- The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) seriesEuropean Journal of Cancer (1965), 1974